Best of ASCO - 2014 Annual Meeting

 

Welcome

Other IO-Related Topics

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi).

Krishna Prasad Joshi

e14255

Analysis of the relationship between ratio N/L and survival in lung cancer patients treated with immunotherapy.

Noemi De Dios Alvarez

e14247

Dipeptidyl peptidase inhibitor BXCL701 synergizes with immunomodulatory agents in a preclinical model of colorectal cancer (CRC) by altering the function of various components of the immune system.

Veena Agarwal

e14253

Discovery of a novel Toll-like Receptor 7 agonist for systemic immunotherapy of cancer.

James Richard Appleman

e14246

Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors.

Diana Roettger

e14245

Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.

Vaia Florou

2617

Gut microbiota and clinical outcomes treated with nivolumab in Chinese non-small cell lung cancer.

Shun Lu

2614

Immune-related adverse events for different age groups using the FDA Adverse Event Reporting System.

Zin Myint

e14256

Immunotherapy-induced endocrinopathies: A multi-center experience.

Karine Ronan

e14251

Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).

Xabier Mielgo

2613

Interleukin-2 boosts local and abscopal antitumor effect of radiotherapy combined with anti-PD-1: A translational research from clinical radio-memory effect.

Dawei Chen

e14244

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

Daniel H. Johnson

2616

New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody.

Grace Zhou

e14250

Pan-tumor prognostic value of multiple immune protein expressions.

Tiphaine Lambert

2618

Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer.

Philip A. Salem

e14254

Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer.

Ying L Liu

2615

Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.

Toshio Sakatani

e14249